Is Acemini included in medical insurance? How much?

Asciminib is a third-generation tyrosine kinase inhibitor (TKI) used to treat chronic myelogenous leukemia (CML), especially in patients who have developed resistance or intolerance to previous generations of TKI drugs. Aceminib acts on the "myristoyl" binding pocket of ABL1kinase, which is different from the mechanism of action of early drugs. Therefore, it can effectively inhibit drug-resistant BCR-ABL proteins including T315I mutations. This property makes Asiminib an important breakthrough in the treatment of CML, especially providing a new treatment option for patients who have failed to respond to other TKIs.

Regarding the price and medical insurance reimbursement of Assimini, Assimini has not yet been officially launched in mainland China, so it cannot be included in China's medical insurance system for reimbursement. If patients need to use Aceminib, they can only purchase the drug through overseas channels. In foreign markets, the original drug of Asiminib mainly comes from Europe, and the price is very high. The price of each box is around tens of thousands of yuan, which is a heavy financial burden for many patients.

For patients who want to spend less on drugs, there are generic drug options. The generic drug of Asiminib produced in Laos is a relatively common choice, with a price of about more than 4,000 yuan, which is much cheaper than the original drug. Although the price of generic drugs is lower, their drug ingredients and efficacy are basically the same as the original drugs, so they have become the first choice for many patients. However, since generic drugs do not enter the Chinese market through formal channels, they cannot be reimbursed through medical insurance.

In general, although Aceminib has high therapeutic value internationally, currently domestic patients can only purchase the drug at their own expense and cannot be reimbursed through medical insurance. For patients, choosing a treatment option that suits them while balancing the financial burden is an important consideration.